Antidepressant-like effects of cannabidiol when combined with temozolomide in adult rats
Frontiers in Pharmacology · 29.06.2026 · 17
DOI: 10.3389/fphar.2026.1873308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.06.2026. Verfasst von Laura Gálvez-Melero und 3 weiteren Autor:innen. Beteiligte Einrichtung: University Research Institute of Health Sciences (IUNICS), University of the Balearic Islands, Palma, Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
There is a need for characterizing more efficacious therapeutic strategies for glioblastoma multiforme to overcome treatment resistance to the standardized use of temozolomide as well as to better treat its debilitating comorbidities like depression. In this context, combination therapies, particularly cannabidiol with temozolomide exhibited additive or synergistic anti-tumor effects, capable of improving temozolomide’s resistance over the course of treatment. Beyond its antitumoral properties and given the promising antidepressant-like profile of cannabidiol, we aimed at evaluating the pharmacological interaction of a combined therapy with cannabidiol and temozolomide as a potential novel antidepressant-like strategy, in comparison with temozolomide’s combination with fluoxetine, the goal treatment standard for depressive-like symptomatology. To do so, adult male and female rats received (i.p.) temozolomide (25 mg/kg, 2 cycles, 5 days/cycle, 1 dose/day), cannabidiol (10 or 30 mg/kg, 3 doses within 24 h), fluoxetine (5–20 mg/kg, 3 doses within 24 h) alone and/or in combination. Antidepressant-like responses were scored under the stress of the forced-swim test. The results proved that all drugs induced antidepressant-like responses, although efficacy was related to sex and the dose administered. Moreover, the combination of fluoxetine with temozolomide was not different than the response induced by each drug separately. However, combining cannabidiol with temozolomide exhibited a sex-dependent antidepressant-like response solely observed in male rats, offering a potential therapeutic avenue to address depression in glioblastoma, where current antidepressants remain largely ineffective. Therefore, we propose that cannabidiol might be a good option to be administered in glioblastoma patients treated with temozolomide for improved affective-like responses, although not before its future validation in animal models of glioblastoma. Moreover, upcoming studies should center in personalizing the doses needed for this combinational approach to be also effective in females.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Research Institute of Health Sciences (IUNICS), University of the Balearic Islands, Palma, Spain.
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain.
- Department of Medicine, University of the Balearic Islands, Palma, Spain.
Zitieren
APA
Gálvez-Melero, L., Ledesma-Corvi, S., Bis-Humbert, C., & García-Fuster, M. J. (2026). Antidepressant-like effects of cannabidiol when combined with temozolomide in adult rats. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1873308
Vancouver
Gálvez-Melero L, Ledesma-Corvi S, Bis-Humbert C, García-Fuster MJ. Antidepressant-like effects of cannabidiol when combined with temozolomide in adult rats. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1873308
BibTeX
@article{GlvezMelero2026,
author = {Gálvez-Melero, Laura and Ledesma-Corvi, Sandra and Bis-Humbert, Cristian and García-Fuster, M Julia},
title = {Antidepressant-like effects of cannabidiol when combined with temozolomide in adult rats},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1873308}
}
EUVIMED